Log In
Print
BCIQ
Print
Print this Print this
 

CR6261

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
Description mAb against influenza
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationInfluenza virus
Indication DetailsTreat H1N1 influenza; Treat influenza A virus infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today